Roche initiated a global Phase III, randomized, double-blind study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalized patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. The study is expected to begin enrolling in June with a target of approximately 450 patients, the trial will enroll globally, including in the United States. In addition to REMDACT...